Intellia Therapeutics is a leading clinical-stage genome editing company, dedicated to developing innovative and potentially curative treatments using CRISPR-based technologies. With a focus on transforming the lives of people with severe diseases, Intellia utilizes a modular lipid nanoparticle delivery system and a strong commitment to product development, making it a pioneer in the field of CRISPR/Cas9 genome editing. Their full-spectrum approach allows for the exploration of a wide range of diseases, as they believe in generating extensive data to uncover the therapeutic potential of CRISPR/Cas9 technology.

Intellia is at the forefront of genome editing, boasting the most advanced CRISPR-based programs in the clinical stage, as well as an impressive collection of emerging tools in development. Join Intellia in their mission to change life stories through genome editing and follow them on social media to stay updated on their groundbreaking advancements. With their commitment to transforming healthcare, Intellia Therapeutics is paving the way for a new era in medicine